Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
EXELIXIS, INC. (EXEL) shares are the subject of a Schedule 13G in which Farallon Capital Management, L.L.C. and its managing members or senior managing members reported shared beneficial ownership of 14,694,910 shares, equal to 6% of the class. Each reporting person reported the same number of shares with shared voting and dispositive power; the eight Farallon Funds hold the shares directly. The named individuals are Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts, Jr., Edric C. Saito, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly. The Farallon Funds have the right to receive dividends and proceeds from sales of the shares.
An amendment concerning EXEL reports that Farallon Capital Management, L.L.C. and the individual reporting persons Hannah E. Dunn, Joshua J. Dapice, Philip D. Dreyfuss, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts Jr., Edric C. Saito, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly each reported shared beneficial ownership of 12,017,906 EXEL common shares, or 4.9% of the class. The percentage is based on 244,010,895 shares outstanding as of October 19, 2026.
The amendment states that transactions in EXEL shares by the Farallon Funds in the past 60 days were all open-market transactions.
Exelixis reported third-quarter 2026 total revenue of $658.696 million, compared with $597.755 million in 2025, and net income of $218.095 million, versus $193.578 million. Net product revenue was $604.924 million, including $603.154 million from CABOMETYX. For the nine months ended September 30, 2026, operating cash flow was $839.542 million, compared with $550.752 million a year earlier.
Takeda’s achievement of $300.0 million in cumulative cabozantinib net sales in Japan triggered an $8.0 million commercial milestone; the tiered royalty rate on annual net sales reset to 20% and will reset each calendar year thereafter. As of September 30, 2026, Exelixis had repurchased 7.4 million shares for $402.1 million under its May 2026 program, with approximately $347.9 million remaining for repurchases before December 31, 2027.
The FDA extended review of the zanzalintinib-and-atezolizumab application by three months after deeming updated safety and efficacy data a major amendment, moving the target action date to March 3, 2027. Exelixis also reported four ongoing pivotal trials of zanzalintinib.
Exelixis reported third-quarter 2026 revenue of $658.7 million, versus $597.8 million a year earlier, and GAAP net income of $218.1 million, versus $193.6 million. GAAP diluted earnings were $0.85 per share and non-GAAP diluted earnings were $0.94. U.S. cabozantinib franchise net product revenue was $604.9 million.
Fiscal 2026 guidance is total revenue of $2.500 billion–$2.550 billion and net product revenue of $2.300 billion–$2.350 billion, excluding revenue from a potential U.S. approval and launch of zanzalintinib for previously treated metastatic colorectal cancer. Effective tax-rate guidance is 16%–18%, versus prior guidance of 21%–23%. FDA review of the zanzalintinib-atezolizumab NDA has a March 3, 2027 target action date; STELLAR-304 topline results are expected in Q1 2027.
At the end of Q3 2026, Exelixis had repurchased $402.1 million of stock at an average $54.03 per share under its authorization of up to $750 million before December 31, 2027. It agreed to grant Azurity a U.S. license for its proposed 505(b)(2) NDA product beginning December 1, 2030, if FDA-approved. In the MSN patent case, the appeals court affirmed the ruling upholding three patents; any final FDA approval of MSN’s ANDA cannot take effect before January 15, 2030, subject to further appellate proceedings, regulatory exclusivity and separate litigation.
Exelixis, Inc. (EXEL) reports that the U.S. Food and Drug Administration has extended by three months the review period for its new drug application for zanzalintinib, in combination with atezolizumab, for patients with metastatic colorectal cancer. The updated Prescription Drug User Fee Act action date is March 3, 2027.
The FDA deemed updated safety and efficacy data submitted by Exelixis to be a major amendment, which triggered the extension of the review timeline.
EXELIXIS, INC. (EXEL) reports a favorable appellate ruling in its cabozantinib patent litigation against MSN Laboratories. On August 31, 2026, the U.S. Court of Appeals for the Federal Circuit affirmed a Delaware district court judgment that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid and dismissed as moot MSN’s appeal regarding U.S. Patent No. 11,298,349, which expires on February 10, 2032.
Based on the ruling, the effective date of any final FDA approval of MSN’s ANDA for its proposed generic product may not be earlier than January 15, 2030, the expiration date of the three affirmed patents, subject to further appeals, regulatory exclusivity, and separate litigation over U.S. Patent No. 12,128,039, which expires in February 2032 and has a trial scheduled to begin in November 2026.
Farallon Capital Management, L.L.C. and affiliated individuals report beneficial ownership of 13,989,010 shares of Exelixis, Inc. common stock, representing 5.6% of the company’s outstanding shares. The ownership is reported on an amended Schedule 13D (Amendment No. 8).
The stake is held through a group of investment partnerships collectively referred to as the Farallon Funds, for which Farallon Capital Management acts as investment manager. The percentage is calculated using 247,781,692 Exelixis shares outstanding as of July 27, 2026. The approximate net investment cost for the Farallon Funds’ position is $308,124,978. Recent trading activity over the prior 60 days, all described as open-market transactions, is detailed in an exhibit referenced in the filing. The filing also formalizes a joint filing agreement among the reporting entities and individuals.
EXELIXIS, INC. director Mary C. Beckerle reported selling 9,812 shares of Common Stock on August 10, 2026 in an open-market transaction at a weighted average price of $53.66 per share, with individual trade prices ranging from $53.16 to $54.02.
After this sale, Beckerle’s reported holdings consist of 16,079 shares, all to be issued upon vesting of restricted stock units, each RSU being the economic equivalent of one share of Common Stock. The sale was executed under a Rule 10b5-1 trading plan adopted on May 8, 2026.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report their beneficial ownership in Exelixis, Inc. common stock. They disclose aggregate beneficial ownership of 11,023,943 shares of common stock, representing 4.39% of the class.
The reporting persons state shared voting power over 10,935,221 shares and shared dispositive power over 11,023,943 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the filing confirms that the Schedule 13G/A is made on behalf of both entities.
Mary Beckerle, a director of Exelixis, Inc., reported a proposed sale of 9,812 common shares, with an aggregate market value of $526,496.22, for approximately August 10, 2026. She acquired the shares from the issuer as restricted stock on May 29, 2026. The notice lists May 8, 2026 as the plan-adoption or instruction date for Rule 10b5-1 reliance.